A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES.
Pinkal M DesaiSagar LonialAmanda F CashenManali KamdarIan W FlinnSusan M O'BrienJacqueline S GarciaNeha KordeJavid J MoslehiMargaret WeyPatricia CheungShringi SharmaDamilola OlabodeHong ChenFirasath Ali SyedMary LiuMarcio Andrade-CamposTapan Mahendra KadiaJames S BlachlyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Treatment with AZD5991 was associated with high incidence of laboratory troponin elevation and a low overall response rate.